Risk of Selecting De Novo Drug-Resistance Mutations during Structured Treatment Interruptions in Patients with Chronic HIV Infection | Zendy

Mireia ArnedoValero | Zendy; Felipe García | Zendy; Cristina Gil | Zendy; T. Guila | Zendy; E. Fumero | Zendy; Pedro Castro | Zendy; José-Luís Blanco | Zendy; Josep M. Miró | Zendy; Tomàs Pumarola | Zendy; José M. Gatell | Zendy

Open Access

Risk of Selecting De Novo Drug-Resistance Mutations during Structured Treatment Interruptions in Patients with Chronic HIV Infection

Author(s) -

Mireia ArnedoValero,

Felipe García,

Cristina Gil,

T. Guila,

E. Fumero,

Pedro Castro,

José-Luís Blanco,

Josep M. Miró,

Tomàs Pumarola,

José M. Gatell

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/432881

Subject(s) - medicine , drug resistance , drug , drug holiday , human immunodeficiency virus (hiv) , viral replication , selection (genetic algorithm) , virology , viral load , sida , hiv drug resistance , replication (statistics) , mutation , immunology , viral disease , antiretroviral therapy , virus , pharmacology , genetics , gene , biology , artificial intelligence , computer science

Structured treatment interruption (STI) may allow viral replication in the presence of decreased plasma drug levels, with risk of selection of resistance mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research